Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Up to 10-years of follow-up data reaffirm safety profile of Mavenclad (cladribine tablets)

worldpharmanewsOctober 12, 2018

Tag: Merck , multiple sclerosis , Mavenclad , Cladribine Tablets

PharmaSources Customer Service